Progyny Inc (PGNY)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $2.66B
Last updated: Nov 17, 2026 at 11:06 AM ET
Progyny Inc (PGNY) P/E Ratio & Valuation History
Progyny (PGNY) trades at 28.0x trailing earnings and 2.1x sales. Its P/E of 28.0x is below its 5-year median of 35.5x. Its forward P/E is 15.2x. The median P/E across 10 similar companies is 48.0x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 84.2% higher over the next year. Its free cash flow yield is 6.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 28.0x |
| Forward P/E | 15.2x |
| Price to sales | 2.1x |
| Price to book | 6.7x |
| EV/EBITDA | 19.0x |
| Price to FCF | 15.4x |
| EV/FCF | 14.7x |
| PEG | N/A |
| FCF yield | 6.5% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 28.0x | 35.5x | N/A |
| P/S | 2.1x | 2.6x | N/A |
| P/B | 6.7x | 5.8x | N/A |
Valuation History
Over the 6 of the 7 year ends shown that have a P/E, its P/E ranged from 10.5x in 2024 to 353.3x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $25.68 | 20.4x | 1.7x | 4.5x |
| 2024 | $17.25 | 10.5x | 1.4x | 3.9x |
| 2023 | $37.18 | 60.0x | 3.3x | 6.8x |
| 2022 | $31.15 | 103.8x | 3.7x | 8.3x |
| 2021 | $50.35 | 76.3x | 9.2x | 20.1x |
| 2020 | $42.39 | 353.3x | 10.9x | 25.1x |
| 2019 | $27.45 | N/A | 2.6x | 15.4x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PGNY
What is PGNY's forward P/E ratio?
Progyny has a forward P/E ratio of 15.2x.
Is PGNY stock overvalued?
GNG's valuation label for PGNY is Fairly valued. Its P/E of 28.0x compares with a median of 48.0x across 10 similar companies.
What is PGNY's price to sales ratio?
Progyny has a price to sales ratio of 2.1x.
What is Progyny's average P/E ratio over 5 years?
Progyny's median P/E over the last 5 years is 35.5x, from 60 month-end values through Oct 2026.
PGNY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors